Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of a-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6J mice

Neuropharmacology

Volumn 73, Issue , 2013, Pages 98-110

  Sathiya, Sekar ^a,b   Ranju, Vijayan ^a,b   Kalaivani, Periyathambi ^a   Priya, Raju Jyothi ^a   Sumathy, Haridass ^a   Sunil, Adoor Gopalan ^a   Babu, Chidambaram Saravana ^a  

^a SRI RAMACHANDRA UNIVERSITY   (India)

^b DR M G R EDUCATIONAL AND RESEARCH INSTITUTE   (India)

Author keywords

BDNF; GDNF; Motor function; MPTP; Telmisartan; synuclein

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3,4 DIHYDROXYPHENYLACETIC ACID; ALPHA SYNUCLEIN; BRAIN DERIVED NEUROTROPHIC FACTOR; DOPAMINE; DOPAMINE TRANSPORTER; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; HOMOVANILLIC ACID; TELMISARTAN; TYROSINE 3 MONOOXYGENASE; VESICULAR MONOAMINE TRANSPORTER 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BDNF GENE; BEAM WALK TEST; CONTROLLED STUDY; CORRELATION ANALYSIS; DAT GENE; DEGENERATIVE DISEASE; DOWN REGULATION; GDNF GENE; GENE; GENE EXPRESSION; GFAP GENE; HORIZONTAL GRID TEST; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; MOTOR PERFORMANCE; MOUSE; NEUROCHEMISTRY; NEUROLOGIC EXAMINATION; NONHUMAN; PARKINSONISM; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STRIDE LENGTH; TH GENE; TRANSCRIPTION REGULATION; UPREGULATION; VERTICAL GRID TEST; VMAT2 GENE;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; 3,4-DIHYDROXYPHENYLACETIC ACID; ANALYSIS OF VARIANCE; ANGIOTENSIN TYPE 1 RECEPTOR; ANOVA; AT1R; BDNF; BRAIN DERIVED NEUROTROPHIC FACTOR; CARBOXY METHYL CELLULOSE; CMC; DAT; DOPAC; DOPAMINE TRANSPORTER; GDNF; GFAP; GLIAL DERIVED NEUROTROPHIC FACTOR; GLIAL FIBRILLARY ACIDIC PROTEINS; HOMOVANILLIC ACID; HVA; I.P.; INTRAPERITONEAL; MOTOR FUNCTION; MPTP; PARKINSON'S DISEASE; PD; RAS; RENIN-ANGIOTENSIN SYSTEM; SEM; SNPC; ST; STANDARD ERROR OF THE MEAN; STRIATUM; SUBSTANTIA NIGRA PARS COMPACTA; SYN; TEL; TELMISARTAN; TH; TYROSINE HYDROXYLASE; VESICULAR MONOAMINE TRANSPORTER 2; VMAT2; Α-SYNUCLEIN;

ALPHA-SYNUCLEIN; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BEHAVIOR, ANIMAL; BENZIMIDAZOLES; BENZOATES; BRAIN-DERIVED NEUROTROPHIC FACTOR; CORPUS STRIATUM; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; GAIT; GENE EXPRESSION; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; GLIAL FIBRILLARY ACIDIC PROTEIN; MALE; MICE; MICE, INBRED C57BL; NERVE DEGENERATION; NEUROPROTECTIVE AGENTS; PARKINSONIAN DISORDERS; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 84885115625     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2013.05.025     Document Type: Article

References (48)

1. Abeliovich, A., Schmitz, Y., Farinas, I., Choi-Lundberg, D., Ho, W.H., Castillo, P.E., Shinsky, N., Verdugo, J.M., Armanini, M., Ryan, A., Hynes, M., Phillips, H., Sulzer, D., Rosenthal, A., 2000. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25, 239-252.
2. Araki, T., Mikami, T., Tanji, H., Matsubara, M., Imai, Y., Mizugaki, M., Itoyama, Y, 2001. Biochemical and immunohistological changes in the brain of 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine (MPTP)-treated mouse. Eur. J. Pharm. Sci. 12, 231-238.
3. Baquet, Z.C., Bickford, P.C., Jones, K.R., 2005. Brain-derived neurotrophic factor is required for the establishment of the proper number of dopaminergic neurons in the substantia nigra pars compacta. J. Neurosci. 25, 6251-6259.
4. Boger, H.A., Middaugh, L.D., Patrick, K.S., Ramamoorthy, S., Denehy, E.D., Zhu, H., Pacchioni, A.M., Granholm, A.C., McGinty, J.F., 2007. Long-term consequences of methamphetamine exposure in young adults are exacerbated in glial cell line-derived neurotrophic factor heterozygous mice. J. Neurosci. 27, 8816-8825.
5. Bradford, M.M., 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254.
6. Chen, M.K., Kuwabara, H., Zhou, Y, Adams, R.J., Brasic, J.R., McGlothan, J.L., Verina, T., Burton, N.C., Alexander, M., Kumar, A., Wong, D.F., Guilarte, T.R., 2008. VMAT2 and dopamine neuron loss in a primate model of Parkinson's disease. J. Neurochem. 105, 78-90.
7. Cianchetti, S., Del Fiorentino, A., Colognato, R., Di Stefano, R., Franzoni, F., Pedrinelli, R., 2008. Anti-inflammatory and anti-oxidant properties of telmisartan in cultured human umbilical vein endothelial cells. Atherosclerosis 198, 22-28.
8. Clayton, D.F., George, J.M., 1998. The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends Neurosci. 21, 249-254.
9. Cookson, M.R., 2005. The biochemistry of Parkinson's disease. Annu. Rev. Biochem. 74, 29-52.
10. Decressac, M., Ulusoy, A., Mattsson, B., Georgievska, B., Romero-Ramos, M., Kirik, D., Bjorklund, A., 2011. GDNF fails to exert neuroprotection in a rat alpha-synuclein model of Parkinson's disease. Brain 134, 2302-2311.
11. Dluzen, D.E., Story, G.M., Xu, K., Kucera, J., Walro, J.M., 1999. Alterations in nigrostriatal dopaminergic function within BDNF mutant mice. Exp. Neurol. 160, 500-507.
12. Emborg, M.E., Ebert, A.D., Moirano, J., Peng, S., Suzuki, M., Capowski, E., Joers, V., Roitberg, B.Z., Aebischer, P., Svendsen, C.N., 2008. GDNF-secreting human neural progenitor cells increase tyrosine hydroxylase and VMAT2 expression in MPTP - treated cynomolgus monkeys. Cell Transplant 17, 383-395.
13. Farina, C., Aloisi, F., Meinl, E., 2007. Astrocytes are active players in cerebral innate immunity. Trends Immunol. 28, 138-145.
14. Feany, M.B., Bender, W.W., 2000. A Drosophila model of Parkinson's disease. Nature 404, 394-398.
15. Fernagut, P.O., Diguet, E., Labattu, B., Tison, F., 2002. A simple method to measure stride length as an index of nigrostriatal dysfunction in mice. J. Neurosci. Methods 113, 123-130.
16. Francis, J.W., Von Visger, J., Markelonis, G.J., Oh, T.H., 1995. Neuroglial responses to the dopaminergic neurotoxicant 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine in mouse striatum. Neurotoxicol. Teratol. 17, 7-12.
17. Garrido-Gil, P., Joglar, B., Rodriguez-Perez, A.I., Guerra, M.J., Labandeira-Garcia, J.L., 2012. Involvement of PPAR-gamma in the neuroprotective and anti-inflammatory effects of angiotensin type 1 receptor inhibition: effects of the receptor antagonist telmisartan and receptor deletion in a mouse MPTP model of Parkinson's disease. J. Neuroinflammation 9, 38.
18. Grammatopoulos, T.N., Jones, S.M., Ahmadi, F.A., Hoover, B.R., Snell, L.D., Skoch, J., Jhaveri, V.V., Poczobutt, A.M., Weyhenmeyer, J.A., Zawada, W.M., 2007. Angiotensin type 1 receptor antagonist losartan, reduces MPTP-induced degeneration of dopaminergic neurons in substantia nigra. Mol. Neurodegener. 2, 1.
19. Grondin, R., Zhang, Z., Yi, A., Cass, W.A., Maswood, N., Andersen, A.H., Elsberry, D.D., Klein, M.C., Gerhardt, G.A., Gash, D.M., 2002. Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced Parkinsonian monkeys. Brain 125, 2191-2201.
20. He, D.Y., Ron, D., 2008. Glial cell line-derived neurotrophic factor reverses ethanolmediated increases in tyrosine hydroxylase immunoreactivity via altering the activity of heat shock protein 90. J. Biol. Chem. 283, 12811-12818.
21. Kasahara, Y., Taguchi, A., Uno, H., Nakano, A., Nakagomi, T., Hirose, H., Stern, D.M., Matsuyama, T., 2010. Telmisartan suppresses cerebral injury in a murine model of transient focal ischemia. Brain Res. 1340, 70-80.
22. Kehoe, P.G., 2009. Angiotensins and Alzheimer's disease: a bench to bedside overview. Alzheimers Res. Ther. 1, 3.
23. Kim, S.T., Son, H.J., Choi, J.H., Ji, I.J., Hwang, O., 2010. Vertical grid test and modified horizontal grid test are sensitive methods for evaluating motor dysfunctions in the MPTP mouse model of Parkinson's disease. Brain Res. 1306, 176-183.
24. Klivenyi, P., Siwek, D., Gardian, G., Yang, L., Starkov, A., Cleren, C., Ferrante, R.J., Kowall, N.W., Abeliovich, A., Beal, M.F., 2006. Mice lacking alpha-synuclein are resistant to mitochondrial toxins. Neurobiol. Dis. 21, 541-548.
25. Kurihara, T., Ozawa, Y., Shinoda, K., Nagai, N., Inoue, M., Oike, Y., Tsubota, K., Ishida, S., Okano, H., 2006. Neuroprotective effects of angiotensin II type 1 receptor (AT1R) blocker, telmisartan, via modulating AT1R and AT2R signaling in retinal inflammation. Invest. Ophthalmol. Vis. Sci. 47, 5545-5552.
26. Luchtman, D.W., Shao, D., Song, C., 2009. Behavior, neurotransmitters and inflammation in three regimens of the MPTP mouse model of Parkinson's disease. Physiol. Behav. 98, 130-138.
27. Martin, L.J., Pan, Y., Price, A.C., Sterling, W., Copeland, N.G., Jenkins, N.A., Price, D.L., Lee, M.K., 2006. Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J. Neurosci. 26, 41-50.
28. Masliah, E., Rockenstein, E., Veinbergs, I., Mallory, M., Hashimoto, M., Takeda, A., Sagara, Y., Sisk, A., Mucke, L., 2000. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 287, 1265-1269.
29. Mertens, B., Vanderheyden, P., Michotte, Y., Sarre, S., 2010. The role of the central renin-angiotensin system in Parkinson's disease. J. Renin Angiotensin Aldosterone Syst. 11, 49-56.
30. O'Callaghan, J.P., Miller, D.B., Reinhard Jr., J.F., 1990. Characterization of the origins of astrocyte response to injury using the dopaminergic neurotoxicant, 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine. Brain Res. 521, 73-80.
31. Pang, T., Wang, J., Benicky, J., Sanchez-Lemus, E., Saavedra, J.M., 2012. Telmisartan directly ameliorates the neuronal inflammatory response to IL-1beta partly through the JNK/c-Jun and NADPH oxidase pathways. J. Neuroinflammation 9, 102.
32. Paxinos, G., Franklin, K.B.J., 2001. The Mouse Brain in Stereotaxic Coordinates, second ed. Academic Press, San Diego.
33. Przedborski, S., Chen, Q., Vila, M., Giasson, B.I., Djaldatti, R., Vukosavic, S., Souza, J.M., Jackson-Lewis, V., Lee, V.M., Ischiropoulos, H., 2001. Oxidative post-translational modifications of alpha-synuclein in the 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. J. Neurochem. 76, 637-640.
34. Rochet, J.C., Liu, F., 2009. Inhibition of α-synuclein aggregation by antioxidants and chaperones in Parkinson's disease. Focus Struct. Biol. 7, 175-206.
35. Savaskan, E., 2005. The role of the brain renin-angiotensin system in neurode-generative disorders. Curr. Alzheimer. Res. 2, 29-35.
36. Schallert, T., 2006. Behavioural tests for preclinical intervention assessment. Neurotherapeutics 3, 497-504.
37. Siegel, G.J., Chauhan, N.B., 2000. Neurotrophic factors in Alzheimer's and Parkinson's disease brain. Brain Res. Rev. 33, 199-227.
38. Stephenson, D., Ramirez, A., Long, J., Barrezueta, N., Hajos-Korcsok, E., Matherne, C., Gallagher, D., Ryan, A., Ochoa, R., Menniti, F., Yan, J., 2007. Quantification of MPTP-induced dopaminergic neurodegeneration in the mouse substantia nigra by laser capture microdissection. J. Neurosci. Methods 159, 291-299.
39. Stromberg, I., Bjorklund, H., Dahl, D., Jonsson, G., Sundstrom, E., Olson, L., 1986. Astrocyte responses to dopaminergic denervations by 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine as evidenced by glial fibrillary acidic protein immunohistochemistry. Brain Res. Bull. 17, 225-236.
40. Taylor, T.N., Caudle, W.M., Miller, G.W., 2011. VMAT2-deficient mice display nigral and extranigral pathology and motor and nonmotor symptoms of Parkinson's disease. Parkinsons Dis. 2011, 124165.
41. Ubhi, K., Rockenstein, E., Mante, M., Inglis, C., Adame, A., Patrick, C., Whitney, K., Masliah, E., 2010. Neurodegeneration in a transgenic mouse model of multiple system atrophy is associated with altered expression of oligodendroglial-derived neurotrophic factors. J. Neurosci. 30, 6236-6246.
42. Visanji, N.P., Orsi, A., Johnston, T.H., Howson, P.A., Dixon, K., Callizot, N., Brotchie, J.M., Rees, D.D., 2008. PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson's disease. FASEB J. 22, 2488-2497.
43. Yavich, L., Oksman, M., Tanila, H., Kerokoski, P., Hiltunen, M., van Groen, T., Puolivali, J., Mannisto, P.T., Garcia-Horsman, A., MacDonald, E., Beyreuther, K., Hartmann, T., Jakala, P., 2005. Locomotor activity and evoked dopamine release are reduced in mice overexpressing A30P-mutated human alpha-synuclein. Neurobiol. Dis. 20, 303-313.
44. Youdim, M.B., Arraf, Z., 2004. Prevention of MPTP (N-methyl-4-phenyl-1,2, 3, 6-tetrahydropyridine) dopaminergic neurotoxicity in mice by chronic lithium: involvements of Bcl-2 and Bax. Neuropharmacology 46, 1130-1140.
45. Yu, Z., Xu, X., Xiang, Z., Zhou, J., Zhang, Z., Hu, C., He, C., 2010. Nitrated alpha-synuclein induces the loss of dopaminergic neurons in the substantia nigra of rats. PLoS One 5, e9956.
46. Yuan, Y., Sun, J., Zhao, M., Hu, J., Wang, X., Du, G., Chen, N.H., 2010. Overexpression of alpha-synuclein down-regulates BDNF expression. Cell Mol. Neurobiol. 30, 939-946.
47. Zhang, L., Coffey, L.L., Reith, M.E., 1997. Regulation of the functional activity of the human dopamine transporter by protein kinase C. Biochem. Pharmacol. 53, 677-688.
48. Zhang, Y., Schlussman, S.D., Rabkin, J., Butelman, E.R., Ho, A., Kreek, M.J., 2013. Chronic escalating cocaine exposure, abstinence/withdrawal, and chronic re-exposure: effects on striatal dopamine and opioid systems in C57BL/6J mice. Neuropharmacology 67, 259-266.